August, 14, 2014, Enigami Newsletter

Thanks to everyone who has signed up for Enigami Medical Cannabis subscriptions ! The first month has been fantastic.

It has been a delight to hear from everyone across the Nation. We wish you good health ! Here are a few notes about what we are up to in the next month or so.

Conferences Scheduled:

September 9, 10, 11, Enigami Medical Cannabis, LLC will be exhibiting at the Denver Medical Marijuana Professionals Conference.

Sept. 11, 2014, Enigami Medical Cannabis, LLC will be present in Minneapolis, Minnesota for a stakeholders conference at the Thompson Hall law firm offices.

Sept. 26th, Enigami Medical Cannabis, LLC will be attending and presenting at the Marijuana Tech Start Up Competition the weekend of September 26th, in Denver.

We’ll also be in attendance at the (Colorado) Marijuana Scientific Advisory Council meetings scheduled through the next few months. If you are in Denver – drop in and watch the process as Colorado decides how to research medical cannabis. Another state with an outstanding approach to medical cannabis treatment is Minnesota. Here is a link to the Minnesota regs: http://www.health.state.mn.us/topics/cannabis/faq.html#track . Minnesota’s inclusion of: “How will the state track the effectiveness and safety of medical cannabis?” and “What are the obligations of patients and health care providers participating in the state’s medical cannabis program?”… are great enhancements to the legitimacy of Dr/Pt relationships, clinical care, and serious Medical Cannabis treatment. They have good thoughts for all the state’s supporting innovations in medical cannabis treatment.

Enigami has opened up a “Ben & Jerry’s” type of competition. We are interested in proposals concerning our knowledge base which is defining the relationships between the cannabinoid combinations (or products) and the various conditions. This knowledge is largely absent from medical cannabis AND the medical field. In the future such knowledge will help educate physicians about recommending, or prescribing, medical cannabis products. It will empower Consumers. This knowledge could be used to guide product development by savvy medical cannabis product developers. It could be used to guide Federal policy, specifically the Veterans Health Administration, and State policy. Should this de-identified aggregate information be published on a Bhutanese mile marker so it may be discovered by an intrepid traveler ? Should a group of medical cannabis stakeholders decide how to disseminate the information ? Should a note be placed in a bottle and thrown out to the dark blue sea ? We’ll accept any creative proposals – even in crayon !

Sign up for the Veterans study is going gangbusters too !!! Some of you persevered through an obscure website glitch dealing with website security…THANK YOU !!!

There are downloadable Posters and Brochures available on the website: http://www.vetptsdstudy.org/ please feel free to use to “get the word out”.

Please submit any support tickets or questions to:
support@enigamisystemsinc.zendesk.com

Have you noticed the news blackout of this study – even in the medical cannabis and Veterans communities ? We’d appreciate hearing your comments on why some folk are trying to suppress medical cannabis research for Veterans with PTSD. Drop a note to us at: info@enigamisystems.com

Please “spread the word” about the Veterans study. We want to finish up the research 10,000 strong.

Scientific Study Factoid for the Day – Observational studies: going beyond the boundaries of randomized controlled trials

– Wenying Yang, Alexey Zilov, Pradana Soewondo, Ole Molskov Bech, Fawzia Sekkal, Philip D. Home (http://www.sciencedirect.com/science/article/pii/S0168822710700024)

Abstract: The term observational study describes a wide range of study designs including prospective and retrospective cohort studies, case-control studies, and cross-sectional studies, a defining feature of which is that any intervention studied is determined by clinical practice and not the protocol. Data from large, prospective observational studies provide information about the safety and efficacy of medicines in daily clinical use. Such observational studies are generally carried out once a medicine has received approval from regulatory agencies. Observational trials have inherent limitations in terms of their susceptibility to bias and confounding, restricting their ability to define causality. However, their strengths include that they reflect daily clinical practice more closely than randomized controlled trials (RCTs), both in terms of the heterogeneous patient populations that are included, and the medical interventions that they receive. Therefore, observational trials can provide clinically relevant information that is not necessarily provided by RCTs. Given the limitations of an observational study approach, it is important to optimize their study design to maximize their validity, and thus, in particular, known causes of bias and confounding should be measured. Medical investigators, health authorities, and the pharmaceutical industry all have important roles to play in designing, approving, and performing observational studies.

July 4, 2014, Enigami Newsletter

Hello Friends and Family,

Enigami Medical Cannabis, LLC (a subsidiary of Enigami Systems, Inc) is proud to be a part of the research outlined in the press release, below.

“Do Veterans, with PTSD, Receive Benefit from Medical Cannabis?” – Questions a National Study of 10,000 Veterans. According to Enigami Systems, Inc. media relations department a national study to determine the effects of medical cannabis treatment for Veterans’ PTSD begins July 4, 2014. The study is eighteen months long and holds great promise for determining effective treatment of Post-traumatic Stress Disorder.

Denver, Colorado (PRWEB) July 04, 2014

It is the opinion of the study group* that when the Veterans Health Administration (the “VA”) re-establishes effective medical programs, the United States will begin, as a Nation, to honor its commitment to the Veteran community. And further it is the opinion of the study group that currently, the V.A. is failing the Veterans as evidenced by the hourly rate of Veteran suicides. (CNN, November 14, 2013, 12:08 p.m., http://www.cnn.com/2013/09/21/us/22-veteran-suicides-a-day/index.html)

Acting Secretary Sloan D. Gibson has stepped into an alarming situation where the Administration has failed (according to the study group) to provide adequate oversight of, or solutions to, the debacle the V.A. is calling a premier healthcare system – especially for those suffering from Post-Traumatic Stress Disorder (PTSD). (White House, Office of the Press Secretary, June 27, 2014, http://www.whitehouse.gov/the-press-office/2014/06/27/readout-president-s-meeting-acting-veterans-affairs-secretary-sloan-gi-0 )

Accompanying the “appointment book cooking,” which is so prominent in the news these days (Time, June 9, 2014, http://time.com/2850879/va-appointment-delays-keep-getting-worse/), the VA has re-instituted failed treatment programs for PTSD (NBC News, June 20, 2014, 9:00 a.m., http://www.nbcnews.com/health/health-news/dod-va-cant-prove-their-ptsd-care-working-study-claims-n136371 ). In the 1990’s, the V.A. learned their specialized inpatient programs were ineffective, and closed them down only to reinstitute them in the last decade (NBC News, June 20, 2014, 9:00 a.m., http://www.nbcnews.com/health/health-news/dod-va-cant-prove-their-ptsd-care-working-study-claims-n136371 ) and according to the study group it may have been to appease the public outcry for effective treatment. That doesn’t make sense. The study group asks, “Why are we funding ineffective programs?”

And so, in the study group’s opinion, a suffering Veteran, maybe one in anyone’s family, commits suicide about every hour because the V.A., and the U.S. as a Nation, has failed to keep their part of the deal – to care for Veteran’s wounds. Some Americans cannot tolerate this situation.

The Departments of Defense and Veterans Affairs spend unbelievably large sums every year to treat post-traumatic stress disorder (NBC News, June 20, 2014, 9:00 a.m., http://www.nbcnews.com/health/health-news/dod-va-cant-prove-their-ptsd-care-working-study-claims-n136371). Collectively they spent $3.294 billion in 2012. But does the treatment help? According to a mandated Congressional report neither the Pentagon nor the VA have a clue about the situation. ( NBC News, June 20, 2014, 9:00 a.m., http://www.nbcnews.com/health/health-news/dod-va-cant-prove-their-ptsd-care-working-study-claims-n136371 )

Adding to the distress and hopelessness Veterans are experiencing, research is impeded or disallowed by the Administration’s bureaucracy. There is a well- established public outcry over a history of “paid for study outcomes” (for “marijuana” research) that are academic nonsense ( Business Insider, August 12, 2013, 4:01 p.m., http://www.businessinsider.com/sanjay-gupta-changed-his-mind-on-weed-2014-4). As recently as this week another promising study, for Veterans suffering from PTSD utilizing Medical Cannabis for treatment, by Dr. Sue Sisley, of the University of Arizona, was blocked by her school administration for advocating research about Medical Cannabis. Dr. Sisley, a heroic academic pioneer, lost her position at the University for advocating the research of a promising treatment option. (Arizona Capitol Times, July 1, 2014, 1:31 p.m., http://azcapitoltimes.com/news/2014/07/01/uofa-medical-marijuana-researcher-sue-sisley-fired-claims-political-motivation/)

Enter Enigami Systems, Inc. owner of a number of patent pending technologies they intend to use to address this through a subsidiary, Enigami Medical Cannabis, LLC.

Enigami Systems, Inc. commercial products help Patients determine the appropriate medical products for effective treatment. Their online application helps a patient determine the relationship of “mainstream medications”, medical cannabis products, and “over the counter products” – and the conditions they are seeking relief from. Currently the knowledge of how effective these interventions are, alone, or in unison, is absent from the medical field.

So, Enigami Medical Cannabis, LLC was formed with an eye to support the Veterans and the PTSD issue. Enigami’s commercial product was tailored to a national study, “Veterans, Post-Traumatic Stress, and Medical Cannabis”, put together by a number of clinicians and Veterans advocates.

Harborside Health Center, the largest Medical Cannabis dispensary in the U.S., located in California, and seen on television’s “Weed Wars”, is listed as an Advisor to promote the study. Though Enigami is providing over $300,000.00 in technology services the study still seeks minimal administrative funding.

The introductory website is: http://www.vetptsdstudy.org and the Study Login/Signup is: https://study.vetptsdstudy.org

The study is free for qualified Veterans who will notice only the absolute minimum of personally identifying information being requested for their personal health records. These records constitute the database for the eighteen (18) month long study. In this study, a Veteran registers, then notes the symptoms of PTSD he/she wishes to track, and decides how often email notices are to be sent as a reminder to record symptom status and medication. This information is translated into an easy to read graph showing treatment progress so that the study participant may determine the best medication approach for his or her care. The record is the personal property of the Veteran study participant with the exception of the aggregate de-identified information which will serve as the answer to the study question, “Do Veterans, with PTSD, derive any treatment benefit from the use of Medical Cannabis?” These personal health records are HIPAA compliant. HIPAA Privacy Rules are the national standards to protect individual’s privacy. The study group has taken additional security measures, as noted on the website security notices. As in all legitimate scientific studies, the project underwent, and will undergo, review by an Institutional Review Board.

The study begins registration and participation on July 4th in honor of the Veterans. At the conclusion of the study the aggregate results will be interpreted and submitted to a professional journal for publication.

The Veterans Health Administration, Congressional leadership, and the Administration will be notified of the de-identified study findings.

*The principals in the study are Patients Out of Time, a national Veteran advocacy organization (Mary Lynn Mathre, RN, MSN, former Lt. in U.S. Navy Nurse Corps, President Al Byrne, LtCdr, retired, U.S. Navy, COO), Enigami Medical Cannabis, LLC (Clifton D. Croan, MA, LPC, DAPA, FAPA, BCPC, DMAPA, William F. Graf, JD), Health Solutions of Arizona, Inc. (Gary D. Miller, DBH, LMSW, CEO), and Global Health & Hygiene Solutions, LLC (Uma Dhanabalan, MD MPH FAAFP, Founder and CEO).